Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1994 Oct;70(828):759–761. doi: 10.1136/pgmj.70.828.759

Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin.

S Sriskandan 1, M E O'Brien 1, I E Smith 1, P Collins 1, M E Gore 1
PMCID: PMC2397792  PMID: 7831179

Abstract

There is a dose-effect relationship between doxorubicin and the incidence of symptomatic cardiac failure. It is generally thought that doses below 500-550 mg/m2 are safe but, when objective measures of cardiac function are used, it becomes apparent that degrees of cardiac failure occur at doses below this. We present here the case histories of two patients who developed very severe cardiac failure at cumulative doses well below 500 mg/m2 but who survived their initial cardiac illness due to aggressive intervention. In one case, the patient was successfully treated by orthotopic cardiac transplantation.

Full text

PDF
759

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldouri M. A., Lopes M. E., Yacoub M., Mitchell A. G., Fox K., Evans T. R., Hoffbrand A. V. Cardiac transplantation for doxorubicin-induced cardiomyopathy in acute myeloid leukaemia. Br J Haematol. 1990 Apr;74(4):541–541. doi: 10.1111/j.1365-2141.1990.tb06349.x. [DOI] [PubMed] [Google Scholar]
  2. Ali M. K., Soto A., Maroongroge D., Bekheit-Saad S., Buzdar A. U., Blumenschein G. R., Hortobagyi G. N., Tashima C. K., Wiseman C. L., Shullenberger C. C. Electrocardiographic changes after adriamycin chemotherapy. Cancer. 1979 Feb;43(2):465–471. doi: 10.1002/1097-0142(197902)43:2<465::aid-cncr2820430210>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  3. Arico M., Nespoli L., Pedroni E., Bonetti F., Vigano M., Burgio G. R. Heart transplantation in a child with doxorubicin-induced cardiomyopathy. N Engl J Med. 1988 Nov 17;319(20):1353–1353. doi: 10.1056/NEJM198811173192015. [DOI] [PubMed] [Google Scholar]
  4. Armitage J. M., Kormos R. L., Griffith B. P., Fricker F. J., Hardesty R. L. Heart transplantation in patients with malignant disease. J Heart Transplant. 1990 Nov-Dec;9(6):627–630. [PubMed] [Google Scholar]
  5. Bristow M. R., Mason J. W., Billingham M. E., Daniels J. R. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978 Feb;88(2):168–175. doi: 10.7326/0003-4819-88-2-168. [DOI] [PubMed] [Google Scholar]
  6. Buzdar A. U., Marcus C., Smith T. L., Blumenschein G. R. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985 Jun 15;55(12):2761–2765. doi: 10.1002/1097-0142(19850615)55:12<2761::aid-cncr2820551206>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
  7. Haq M. M., Legha S. S., Choksi J., Hortobagyi G. N., Benjamin R. S., Ewer M., Ali M. Doxorubicin-induced congestive heart failure in adults. Cancer. 1985 Sep 15;56(6):1361–1365. doi: 10.1002/1097-0142(19850915)56:6<1361::aid-cncr2820560624>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  8. Hortobagyi G. N., Frye D., Buzdar A. U., Ewer M. S., Fraschini G., Hug V., Ames F., Montague E., Carrasco C. H., Mackay B. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer. 1989 Jan 1;63(1):37–45. doi: 10.1002/1097-0142(19890101)63:1<37::aid-cncr2820630106>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  9. Lüthy A., Furrer M., Waser M., Maggiorini M., Pluess H. J., Real F., Weiss B., Gallino A., Turina M. Orthotopic heart transplantation: an efficient treatment in a young boy with doxorubicin-induced cardiomyopathy. J Heart Lung Transplant. 1992 Jul-Aug;11(4 Pt 1):815–816. [PubMed] [Google Scholar]
  10. McKillop J. H., Bristow M. R., Goris M. L., Billingham M. E., Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J. 1983 Nov;106(5 Pt 1):1048–1056. doi: 10.1016/0002-8703(83)90651-8. [DOI] [PubMed] [Google Scholar]
  11. McManus R. P., O'Hair D. P. Pediatric heart transplantation for doxorubicin-induced cardiomyopathy. J Heart Lung Transplant. 1992 Mar-Apr;11(2 Pt 1):375–376. [PubMed] [Google Scholar]
  12. Neri B., Cini-Neri G., Bandinelli M., Pacini P., Bartalucci S., Ciapini A. Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects. Int J Clin Pharmacol Ther Toxicol. 1989 May;27(5):217–221. [PubMed] [Google Scholar]
  13. Palmeri S. T., Bonow R. O., Myers C. E., Seipp C., Jenkins J., Green M. V., Bacharach S. L., Rosenberg S. A. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol. 1986 Sep 15;58(7):607–613. doi: 10.1016/0002-9149(86)90284-5. [DOI] [PubMed] [Google Scholar]
  14. Speyer J. L., Green M. D., Kramer E., Rey M., Sanger J., Ward C., Dubin N., Ferrans V., Stecy P., Zeleniuch-Jacquotte A. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988 Sep 22;319(12):745–752. doi: 10.1056/NEJM198809223191203. [DOI] [PubMed] [Google Scholar]
  15. Von Hoff D. D., Layard M. W., Basa P., Davis H. L., Jr, Von Hoff A. L., Rozencweig M., Muggia F. M. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710–717. doi: 10.7326/0003-4819-91-5-710. [DOI] [PubMed] [Google Scholar]
  16. Yeung S. T., Yoong C., Spink J., Galbraith A., Smith P. J. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet. 1991 Apr 6;337(8745):816–818. doi: 10.1016/0140-6736(91)92516-5. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES